Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
74.09
+1.93 (2.67%)
Nov 3, 2026, 10:11 AM EST - Market open
Inhibrx Biosciences Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Inhibrx Biosciences stock has a consensus rating of "Buy" and an average price target of $266.67. The average 1-year stock price forecast is 259.93% higher than the current stock price, while the lowest is $230 (+210.43%) and the highest is $325 (+338.66%).
Price Target: $266.67 (+259.93%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Inhibrx Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $325 | Buy | Maintains | $325 | +338.66% | Oct 29, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $245 | Buy | Reiterates | $245 | +230.68% | Sep 9, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $230 | Buy | Maintains | $230 | +210.43% | Sep 8, 2026 |
Financial Forecast
Revenue This Year
n/a
from 1.30M
Decreased by -100.00%
Revenue Next Year
36.05M
EPS This Year
-9.26
from -9.04
EPS Next Year
-8.76
from -9.26
EPS and Forward PE are based on non-GAAP adjusted numbers.